Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-02-03
2009-08-11
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C435S325000, C435S326000
Reexamination Certificate
active
07572896
ABSTRACT:
The invention provides characterization of the disease and cancer-associated antigen, OSM-R.beta. The invention also provides modulators of OSM-R.beta, including a family of monoclonal antibodies that bind to antigen OSM-R.beta, and methods of diagnosing and treating various human cancers and diseases associated with OSM-R.beta.
REFERENCES:
patent: 3842067 (1974-10-01), Sarantakis
patent: 3862925 (1975-01-01), Sarantakis et al.
patent: 3972859 (1976-08-01), Fujino et al.
patent: 4105603 (1978-08-01), Vale, Jr. et al.
patent: RE30548 (1981-03-01), Vale, Jr. et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5552391 (1996-09-01), Coutts et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5656444 (1997-08-01), Webb et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5925740 (1999-07-01), Mosley et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6265150 (2001-07-01), Terstappen et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 6541225 (2003-04-01), Li
patent: 2003/0223998 (2003-12-01), Lamb et al.
patent: 0 519 596 (1992-12-01), None
patent: 0 519 596 (1992-12-01), None
patent: WO-01/43869 (2001-06-01), None
patent: WO-01/43869 (2001-06-01), None
Mosley et al., J Biol Chem. vol. 271, p. 32635-32643, 1996.
Aruffo, A. et al. (Dec. 1987). “Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System,”Proc. Natl. Acad. Sci. USA84:8573-8577.
Bird, R E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,”Science242:423-426.
Brown, B.A. et al. (Jul. 1, 1987). “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,”Cancer Res. 47:3577-3583.
Carter, P. et al. (May 1992). “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,”Proc. Natl. Acad. Sci. USA89:4285-4289.
Cawston, T.E. (Oct. 4, 1995). “Interleukin-1 and Oncostatin M in Combination Promote the Release of Collagen Fragments From Bovine Nasal Cartilage in Culture,”Biochemical&Biophysical Research Communications215(1):377-385.
Co, M.S. et al. (Apr. 1991). “Humanized Antibodies for Antiviral Therapy,”Proc. Natl. Acad. Sci. USA88:2869-2873.
Co, M.S. et al. (Feb. 15, 1992), “Chimeric and Humanized Antibodies With Specificity for the CD33 Antigen,”J. Immunol.148(4):1149-1154.
Daugherty, B.L. et al. (1991). “Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonai Antibody Directed Against the CD18 Component of Leukocyte Integrins,”Nucl. Acids Res. 19(9):2471-2476.
Dean, P.D.G. et al. eds. (1985).Affinity Chromatography: A Practical ApproachIRL Press, Ltd., pp. vii-xiv (Table of Contents Only.).
Dillman, R.O. et al. (Nov. 1, 1988). “Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug,”Cancer Res. 48:6097-6102.
Gennaro, A.R. ed. (2000).Remington: The Science and Practice of Pharmacy20th Edition, Lippincott Williams and Wilkins, pp. xiv-xv (Table of Contents Only.).
Goldenberg, D.M. ed. (1995).Cancer Therapy With Radiolabeled Antibodies, CRC Press: Boca Raton, FL, two pages. (Tables of Contents Only.).
Gorman, S.D. et al. (May 1991). “Reshaping a Therapeutic CD4 Antibody,”Proc Natl. Acad. Sci. USA88:4181-4185.
Grötzinger, J. et al. (1997). “The Family of the IL-6-Type Cytokines: Specificity and Promiscuity of the Receptor Complexes,”Proteins27(1):96-109.
Horn, D. et al. (1990). “Regulation of Cell Growth by Recombinant Oncostatin M,”Growth Factors2(2-3):157-165.
Houghten, R.A. (Aug. 1965). “General Method for the Rapid Solid-Phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids,”Proc. Natl. Acad. Sci. USA82(15):5131-5135.
Jones, P.T. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,”Nature321:522-525.
Kelley, R. F. et al. (1990). “Folding of Eukaryolic Proteins Produced inEscherichia coli” In Genetic Engineering: Principles and Methods, Setlow, J.K. et al. eds. Plenum Press: New York, NY. vol. 12, pp. 1-19.
Kettleborough, C.A. et al. (1991). “Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: The Importance of Framework Residues on Loop Conformation,”Protein Engineering4(7):773-783.
Köhler, G. et al. (Aug. 7, 1975). “Continuous Cultures of Fused Cells Secreting Anitbody of Predefined Specificity,”Nature256:495-497.
LoBuglio, A.F. et al, (Jun. 1989). “Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response,”Proc. Natl. Acad. Sci.USA86:4420-4224.
Lonberg, N. et al. (1995). “Human Antibodies from Transgenic Mice,”Int. Rev. Immunol.13:65-93.
Lowe, C.R. (1979). “An Introduction to Affinity Chromatography”In Laboratory Techniques in Biochemistry and Molecular Biology, Work, T.S. et al. eds. North-Holland Publishing Company, vol. 7, Part II, pp. 269-273 (Table of Contents Only.).
Maeda, H. et al. (Jul. 1991). “Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity,”Human Antibodies Hybridomas2:124-134.
Mahato, R.I. et al. (1997). “Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives,”Pharm. Res. 14(7):853-859.
Mangham, D.C. et al. (1999). “A Novel Immunohistochemical Detection System Using Mirror Image Complementary Antibodies (MICA),”Histopathology35(2):129-133.
Merrifield, R.B. (Jul. 20, 1963). “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,”J. Am. Chem. Soc. 85:2149-2154.
Modur, V. et al. (Jul. 1997).“Oncostatin M Is a Proinflammatory Mediator,”J. Clin. Invest. 100(1):158-168.
Mosley, B. et al. (Dec. 20, 1996). “Dual Oncostatin M (OSM) Receptors,”Journal of Biological Chemistry271(50):32635-32643.
Peeters, K. et al. (2001). “Production of Antibodies and Antibody Fragments in Plants,”Vaccine19:2756-2761.
Pollock, D.P. et al. (1999). “Transgenic Milk as a Method for the Production of Recombinant Antibodies,”J. Immunol. Methods231:147-157.
Porath, J. et al. (1975). “Biospecific Affinity Chromatography and Related Methods,” Chaper 2 InThe Proteins, Third Edition, Neurath, H. et al. eds., Academic Press, Inc., vol. 1, pp. 95-178.
Riechmann, L. et al. (Mar. 24, 1988). “Reshaping Human Antibodies for Theraphy,”Nature332:323-327.
Rose, T.M. et al. (Oct. 1991)“Oncostatin M is a Member of a Cytokine Family that Includes Leukemia-Inhibitory Factor, Granulocyte Colony-Stimulating Factor, and Interleukin 6,”Proc. Natl. Acad. Sci. USA88(19):8641-8645.
Sato, K. et al. (Feb. 15, 1993). “Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth,”Cancer Res. 53:851-856.
Schott, H. (1984).Affinity Chromatography: Template Chromatography of Nucleic Acids and Proteins, Marcel Dekker, Inc.: New York, NY, pp. v-vii (Table of Contents Only.).
Shaw, D.R. et al. (Jun. 15, 1987). “Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen,”J. Immunology138(12):4534-4538.
Shen, W-C. et al. (Oct. 15, 1981). “Cis-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of pH-Sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate,”Biochem. Biophys. Res. Commun.102(3):1048-1054.
Stephan, J-P. et al. (1999). “Distribution and Function of the Adhesion Molecule BE
Mather Jennie P.
Roberts Penelope E.
Helms Larry R.
Morrison & Foerster / LLP
Raven biotechnologies, Inc.
Yao Lei
LandOfFree
Antibodies to oncostatin M receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to oncostatin M receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to oncostatin M receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103243